Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAF V600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial Read More Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma Read More Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial Read More A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma Read More The Landmark Series: Neoadjuvant Systemic Therapy (NAST) for Stage 3 Melanoma Patients - A Potential Paradigm Shift in Management Read More Click Here To Contact Us If You Cannot Access An Article